NFE2L2 and cancer: This study demonstrates that NRF2 activation, either through pharmacological inhibition of KEAP1 or genetic mutations, leads to an imbalance in the NADH/NAD+ ratio, which disrupts mitochondrial function and sensitizes cancer cells to Complex I inhibition [180].